Literature DB >> 16673017

Human telomerase reverse transcriptase protects hematopoietic progenitor TF-1 cells from death and quiescence induced by cytokine withdrawal.

S Li1, M J Ferguson, C J Hawkins, C Smith, N J Elwood.   

Abstract

Telomerase is a complex ribonucleoprotein enzyme that exhibits elevated activity in the majority of cases of human leukemia. We have previously shown that retroviral expression of the catalytic subunit of telomerase, human telomerase reverse transcriptase (hTERT), in human cord blood CD34+ cells leads to an enhanced survival of mature hematopoietic cells. The mechanism for this pro-survival effect is not known. Here, we show that telomerase may play a role in leukemogenesis as a survival factor, independent of its role in maintaining telomere length. Retroviral expression of hTERT in the cytokine-dependent, human hematopoietic progenitor cell line, TF-1, resulted in the survival of cells following the withdrawal of cytokine, with protection from apoptosis, but did not promote unlimited replicative potential. This hTERT-mediated effect on cell survival does not involve Bcl-2 family members, results in accumulation of cells in G1 and appears to operate via autocrine expression of IL-3 and activation of the p53/p21 pathway. Survival in the absence of cytokine stimulation was also observed following retroviral expression of hTERT in normal cord blood CD34+ cells. This study demonstrates a novel pro-survival role for hTERT and may have important implications for the role of hTERT in the pathogenesis of leukemia and drug resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16673017     DOI: 10.1038/sj.leu.2404251

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Correction of copper metabolism is not sustained long term in Wilson's disease mice post bone marrow transplantation.

Authors:  Nicole E Buck; Daphne M Y Cheah; Ngaire J Elwood; Paul F A Wright; Katrina J Allen
Journal:  Hepatol Int       Date:  2007-12-28       Impact factor: 6.047

Review 2.  New prospects for targeting telomerase beyond the telomere.

Authors:  Greg M Arndt; Karen L MacKenzie
Journal:  Nat Rev Cancer       Date:  2016-06-24       Impact factor: 60.716

Review 3.  Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications.

Authors:  Tiantian Liu; Xiaotian Yuan; Dawei Xu
Journal:  Genes (Basel)       Date:  2016-07-18       Impact factor: 4.096

4.  Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancer.

Authors:  Nirosha Suraweera; Dmitri Mouradov; Shan Li; Robert N Jorissen; Debbie Hampson; Anil Ghosh; Neel Sengupta; Mohamed Thaha; Shafi Ahmed; Michael Kirwan; Floor Aleva; David Propper; Roger M Feakins; Tom Vulliamy; Ngaire J Elwood; Pei Tian; Robyn L Ward; Nicholas J Hawkins; Zheng-Zhou Xu; Peter L Molloy; Ian T Jones; Matthew Croxford; Peter Gibbs; Andrew Silver; Oliver M Sieber
Journal:  Oncotarget       Date:  2016-06-14

5.  MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.

Authors:  Xiaolu Zhang; Bingnan Li; Jingya Yu; Jenny Dahlström; Anh Nhi Tran; Magnus Björkholm; Dawei Xu
Journal:  Ann Hematol       Date:  2017-10-27       Impact factor: 3.673

6.  The Telomerase Complex Directly Controls Hematopoietic Stem Cell Differentiation and Senescence in an Induced Pluripotent Stem Cell Model of Telomeropathy.

Authors:  Shyam Sushama Jose; Federico Tidu; Petra Burilova; Tomas Kepak; Kamila Bendickova; Jan Fric
Journal:  Front Genet       Date:  2018-08-29       Impact factor: 4.599

7.  TIMP-2 regulates 5-Fu resistance via the ERK/MAPK signaling pathway in colorectal cancer.

Authors:  Guolin Zhang; Xin Luo; Zian Wang; Jianbin Xu; Wei Zhang; Engeng Chen; Qing Meng; Di Wang; Xuefeng Huang; Wei Zhou; Zhangfa Song
Journal:  Aging (Albany NY)       Date:  2022-01-12       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.